Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obsessive-Compulsive Disorder | 14 | 2025 | 831 | 2.200 |
Why?
|
| Opioid-Related Disorders | 7 | 2025 | 284 | 1.390 |
Why?
|
| Neonatal Abstinence Syndrome | 3 | 2025 | 20 | 1.300 |
Why?
|
| Analgesics, Opioid | 7 | 2025 | 465 | 1.110 |
Why?
|
| Electronic Health Records | 4 | 2024 | 804 | 1.050 |
Why?
|
| Empyema | 1 | 2022 | 24 | 0.790 |
Why?
|
| Evoked Potentials | 1 | 2022 | 121 | 0.750 |
Why?
|
| Osteogenesis Imperfecta | 4 | 2025 | 168 | 0.740 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2025 | 855 | 0.710 |
Why?
|
| Algorithms | 3 | 2024 | 1713 | 0.700 |
Why?
|
| International Classification of Diseases | 2 | 2019 | 98 | 0.690 |
Why?
|
| Pneumococcal Infections | 1 | 2022 | 276 | 0.670 |
Why?
|
| Sodium Lactate | 1 | 2019 | 2 | 0.620 |
Why?
|
| Telemedicine | 2 | 2024 | 505 | 0.620 |
Why?
|
| Computer Communication Networks | 1 | 2019 | 16 | 0.610 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 70 | 0.590 |
Why?
|
| Panic Disorder | 1 | 2019 | 52 | 0.590 |
Why?
|
| Clinical Coding | 1 | 2018 | 15 | 0.580 |
Why?
|
| Carbon Dioxide | 1 | 2019 | 284 | 0.560 |
Why?
|
| Patient Discharge | 2 | 2020 | 515 | 0.550 |
Why?
|
| Electroencephalography | 1 | 2022 | 905 | 0.550 |
Why?
|
| Medical Records | 1 | 2018 | 190 | 0.540 |
Why?
|
| Patient-Centered Care | 2 | 2020 | 234 | 0.530 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 2278 | 0.500 |
Why?
|
| Mental Disorders | 1 | 2024 | 891 | 0.490 |
Why?
|
| Pandemics | 5 | 2022 | 1187 | 0.460 |
Why?
|
| Phenotype | 2 | 2024 | 4544 | 0.460 |
Why?
|
| Influenza, Human | 1 | 2021 | 699 | 0.450 |
Why?
|
| Morphine | 2 | 2025 | 85 | 0.380 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 1410 | 0.370 |
Why?
|
| Humans | 38 | 2025 | 132049 | 0.370 |
Why?
|
| Tennessee | 3 | 2025 | 34 | 0.360 |
Why?
|
| Adult | 20 | 2025 | 31576 | 0.320 |
Why?
|
| Chronic Pain | 2 | 2024 | 149 | 0.310 |
Why?
|
| United States | 9 | 2025 | 11620 | 0.300 |
Why?
|
| Aged | 10 | 2025 | 21317 | 0.290 |
Why?
|
| Middle Aged | 15 | 2025 | 28827 | 0.290 |
Why?
|
| Young Adult | 10 | 2025 | 9934 | 0.270 |
Why?
|
| Adolescent | 11 | 2025 | 20513 | 0.270 |
Why?
|
| Psychometrics | 3 | 2025 | 694 | 0.260 |
Why?
|
| Female | 23 | 2025 | 70672 | 0.260 |
Why?
|
| Male | 21 | 2025 | 64891 | 0.250 |
Why?
|
| Culturally Competent Care | 2 | 2024 | 51 | 0.250 |
Why?
|
| Qualitative Research | 3 | 2025 | 659 | 0.250 |
Why?
|
| Medicaid | 2 | 2019 | 245 | 0.250 |
Why?
|
| Uncertainty | 2 | 2023 | 103 | 0.240 |
Why?
|
| Academic Performance | 1 | 2025 | 25 | 0.230 |
Why?
|
| Academic Success | 1 | 2025 | 23 | 0.230 |
Why?
|
| Reproducibility of Results | 5 | 2025 | 3019 | 0.230 |
Why?
|
| Opiate Substitution Treatment | 1 | 2024 | 32 | 0.220 |
Why?
|
| Consumer Health Information | 1 | 2025 | 29 | 0.220 |
Why?
|
| Reward | 1 | 2025 | 119 | 0.220 |
Why?
|
| Adaptation, Psychological | 2 | 2025 | 453 | 0.220 |
Why?
|
| Hospitalization | 3 | 2024 | 1901 | 0.220 |
Why?
|
| Benchmarking | 1 | 2025 | 144 | 0.220 |
Why?
|
| Self Report | 2 | 2024 | 551 | 0.210 |
Why?
|
| Gender Identity | 1 | 2024 | 73 | 0.210 |
Why?
|
| Reproductive Health | 1 | 2024 | 49 | 0.210 |
Why?
|
| Interview, Psychological | 1 | 2024 | 108 | 0.210 |
Why?
|
| Buprenorphine | 1 | 2024 | 101 | 0.210 |
Why?
|
| Evidence-Based Practice | 1 | 2024 | 114 | 0.210 |
Why?
|
| Video Recording | 1 | 2025 | 202 | 0.200 |
Why?
|
| Incidence | 2 | 2022 | 3362 | 0.200 |
Why?
|
| Anticipation, Psychological | 1 | 2022 | 6 | 0.200 |
Why?
|
| Students | 1 | 2025 | 263 | 0.200 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 78 | 0.200 |
Why?
|
| Retrospective Studies | 8 | 2025 | 17308 | 0.200 |
Why?
|
| Implosive Therapy | 1 | 2024 | 98 | 0.200 |
Why?
|
| Family | 1 | 2025 | 596 | 0.190 |
Why?
|
| Pain Management | 1 | 2024 | 199 | 0.180 |
Why?
|
| Depressive Disorder | 1 | 2025 | 481 | 0.180 |
Why?
|
| Radiosurgery | 1 | 2023 | 147 | 0.180 |
Why?
|
| Pregnancy | 5 | 2025 | 7552 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2025 | 344 | 0.180 |
Why?
|
| Pneumococcal Vaccines | 1 | 2022 | 172 | 0.180 |
Why?
|
| Electrophysiology | 1 | 2021 | 268 | 0.180 |
Why?
|
| Fractures, Bone | 1 | 2023 | 207 | 0.170 |
Why?
|
| Psychotherapy | 1 | 2024 | 247 | 0.170 |
Why?
|
| Autistic Disorder | 1 | 2024 | 379 | 0.170 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 7097 | 0.170 |
Why?
|
| Referral and Consultation | 1 | 2024 | 570 | 0.160 |
Why?
|
| Caregivers | 1 | 2025 | 595 | 0.160 |
Why?
|
| Seasons | 1 | 2021 | 329 | 0.160 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 188 | 0.150 |
Why?
|
| Fentanyl | 1 | 2019 | 53 | 0.150 |
Why?
|
| Autism Spectrum Disorder | 1 | 2024 | 429 | 0.150 |
Why?
|
| Methadone | 1 | 2019 | 124 | 0.150 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 65 | 0.150 |
Why?
|
| Administration, Inhalation | 1 | 2019 | 182 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2024 | 698 | 0.150 |
Why?
|
| Anxiety Disorders | 1 | 2024 | 733 | 0.140 |
Why?
|
| Child | 8 | 2025 | 25779 | 0.140 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 566 | 0.140 |
Why?
|
| Infant, Newborn | 3 | 2025 | 8501 | 0.130 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 3067 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 480 | 0.130 |
Why?
|
| Depression | 1 | 2025 | 1352 | 0.120 |
Why?
|
| Genomics | 1 | 2023 | 1644 | 0.120 |
Why?
|
| Quality of Life | 1 | 2025 | 2150 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 672 | 0.110 |
Why?
|
| Latin America | 2 | 2024 | 99 | 0.100 |
Why?
|
| Meningitis, Fungal | 1 | 2012 | 6 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2025 | 428 | 0.100 |
Why?
|
| Drug Contamination | 1 | 2012 | 38 | 0.100 |
Why?
|
| Methylprednisolone | 1 | 2012 | 96 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2023 | 12883 | 0.090 |
Why?
|
| Hypertension | 1 | 2020 | 1341 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2022 | 6509 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 329 | 0.090 |
Why?
|
| Infant | 2 | 2023 | 13113 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2012 | 387 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 5142 | 0.080 |
Why?
|
| Pharmacoepidemiology | 1 | 2025 | 11 | 0.060 |
Why?
|
| Prognosis | 2 | 2025 | 4992 | 0.060 |
Why?
|
| Spain | 1 | 2025 | 65 | 0.060 |
Why?
|
| Drug Labeling | 1 | 2025 | 30 | 0.060 |
Why?
|
| Risk Factors | 1 | 2019 | 10834 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2025 | 159 | 0.060 |
Why?
|
| Data Accuracy | 1 | 2024 | 34 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 1 | 2025 | 236 | 0.060 |
Why?
|
| Transgender Persons | 1 | 2024 | 68 | 0.050 |
Why?
|
| ROC Curve | 1 | 2025 | 597 | 0.050 |
Why?
|
| Schools | 1 | 2025 | 238 | 0.050 |
Why?
|
| Urban Population | 1 | 2024 | 244 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2024 | 209 | 0.050 |
Why?
|
| Cultural Competency | 1 | 2024 | 53 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2024 | 229 | 0.050 |
Why?
|
| Social Support | 1 | 2025 | 387 | 0.050 |
Why?
|
| Rural Population | 1 | 2024 | 281 | 0.050 |
Why?
|
| Infant Mortality | 1 | 2023 | 177 | 0.050 |
Why?
|
| Fear | 1 | 2023 | 204 | 0.050 |
Why?
|
| Electrodes | 1 | 2021 | 90 | 0.050 |
Why?
|
| Ventral Striatum | 1 | 2021 | 43 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2024 | 325 | 0.040 |
Why?
|
| Sulfonylurea Compounds | 1 | 2020 | 19 | 0.040 |
Why?
|
| Psychiatry | 1 | 2024 | 271 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1501 | 0.040 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2020 | 30 | 0.040 |
Why?
|
| Mothers | 1 | 2023 | 373 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2020 | 81 | 0.040 |
Why?
|
| Inpatients | 1 | 2024 | 551 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 239 | 0.040 |
Why?
|
| Cognition | 1 | 2024 | 809 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 819 | 0.040 |
Why?
|
| Metformin | 1 | 2020 | 165 | 0.040 |
Why?
|
| Length of Stay | 1 | 2024 | 1375 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1302 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 275 | 0.030 |
Why?
|
| Parents | 1 | 2024 | 1074 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1165 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1829 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5370 | 0.030 |
Why?
|
| Insulin | 1 | 2020 | 1219 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 3655 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1603 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 765 | 0.030 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2012 | 9 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 2012 | 44 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2012 | 43 | 0.020 |
Why?
|
| Ascomycota | 1 | 2012 | 26 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2012 | 136 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 3355 | 0.020 |
Why?
|
| Biomarkers | 1 | 2021 | 3386 | 0.020 |
Why?
|
| Public Health | 1 | 2012 | 282 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2012 | 311 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 1065 | 0.010 |
Why?
|